The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as non-alcoholic fatty liver disease (NAFLD)—is the most common chronic liver disease worldwide. Since there is currently no approved pharmacotherapy for MASLD, there is an urgent unmet need for efficacious therapeutics...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Yvonne Burmeister, Kathrin Weyer, Achim Dörre, Bernd Seilheimer
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2023-12-01
Reeks:	Biomedicines
Onderwerpen:	non-alcoholic fatty liver disease (NAFLD) non-alcoholic steatohepatitis (NASH) metabolic dysfunction-associated steatotic liver disease (MASLD) metabolic dysfunction-associated steatohepatitis (MASH) liver fibrosis
Online toegang:	https://www.mdpi.com/2227-9059/11/12/3216
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!